Mexican Emerging Infectious Diseases Clinical Research Network
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
1 terminated/withdrawn out of 6 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Role: collaborator
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Role: lead
Evaluation of Culture Negative Severe Acute Respiratory Infection in Mexico
Role: lead
Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Role: collaborator
A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico
Role: lead
Characterization of Influenza-like Illness in Mexico
Role: lead
All 6 trials loaded